<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02493231</url>
  </required_header>
  <id_info>
    <org_study_id>2014-10-133</org_study_id>
    <nct_id>NCT02493231</nct_id>
  </id_info>
  <brief_title>Effect of Intraoperative Nefopam on Acute Pain After Remifentanil Based Anesthesia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hallym University Kangnam Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hallym University Kangnam Sacred Heart Hospital</source>
  <brief_summary>
    <textblock>
      Many anesthesiologists use the Remifentanil for reducing a surgical pain and stabilizing a
      vital sign. However, this drug induce postoperative hyperalgesia. Nowadays, many studies
      report that low-dose Ketamine prevents the opioid-induces hyperalgesia. Nefopam,which is
      non-opioid analgesic, has similar mechanism with Ketamine. It will be helpful for
      postoperative pain control, and reduce the needs of opioid.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>analgesic requirement</measure>
    <time_frame>During 1 hour at PACU</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>duration of analgesic free</measure>
    <time_frame>During 1 hour at PACU</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>analgesic requirement</measure>
    <time_frame>During 8 hours after arriving at ward</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain on the VAS scale</measure>
    <time_frame>During 1 hour at PACU</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cholecystitis</condition>
  <arm_group>
    <arm_group_label>Nefopam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The generic name is 'ACUPAN'. It is infused during operation. A induction dose is 0.3mg/Kg. A maintenance dose is 65 mcg/kg/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>It is infused during operation. A induction dose is 0.3 mg/Kg. A maintenance dose is 3 mcg/kg/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>It is infused during operation. A induction volume is 3mL A maintenance dose is 10mL/hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nefopam</intervention_name>
    <arm_group_label>Nefopam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient who scheduled laparoscopic cholecystectomy under general anesthesia

          -  American Society of Anesthesiologist(ASA) class I or II

          -  adult patient (age 20 - 65)

        Exclusion Criteria:

          -  patient who has liver disease

          -  patient who has kidney disease

          -  patient who has diabetes mellitus(DM) or heart disease

          -  patient who takes opioid or beta-blocker

          -  patient who has airway disease

          -  patient who has allergy with the drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Mi hyun Lee</last_name>
    <phone>+82-02-829-5230</phone>
    <email>md1212@naver.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hallym University Kangnam Sacred Heart Hospita</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haejin Son</last_name>
      <phone>+82-02-829-5527</phone>
      <email>dandelionc@hallym.or.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2015</study_first_submitted>
  <study_first_submitted_qc>July 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2015</study_first_posted>
  <last_update_submitted>August 31, 2015</last_update_submitted>
  <last_update_submitted_qc>August 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hallym University Kangnam Sacred Heart Hospital</investigator_affiliation>
    <investigator_full_name>Lee Mi Hyeon</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecystitis</mesh_term>
    <mesh_term>Acalculous Cholecystitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Nefopam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

